
Your Feed
Real-World Schedule De-escalation of Teclistamab in Patients with RRMM | Carlyn Tan, MD | EHA 2024
Phase 1b-2 Dose Escalation Study Sonrotoclax + Dexamethasone | Binod Dhakal, MD | EHA 2024
CARTITUDE-4 Subgroup Analysis of Functional High-Risk Patients | Luciano Costa, MD | EHA 2024
Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 Trial | Luciano Costa, MD | EHA 2024
MAJESTIC-1 Study - A Subgroup Analysis of High-risk Patients | Luciano Costa, MD | EHA2024
ASCO/EHA Myeloma Updates 2024 | Claudio Cerchione, MD | EHA 2024
The Role of Combination FDG PET Plus Whole Body MRI for Staging | Claudio Cerchione, MD | EHA 2024
Bispecific Antibodies and Precision Medicine Insights on Myeloma Prognosis | Ola Landgren, MD | EHA 2024
Real World Outcomes of RRMM Using Kyprolis | Sharlene Dong, MD, MS | EHA 2024
Integrating BCMA-Targeted Therapies into Challenging Myeloma Cases | Rakesh Popat, PhD | EHA 2024
Treating RRMM with Bispecific Antibodies | Rakesh Popat, PhD | EHA 2024
Managing the Unique Side Effects of Talquetamab | Ajai Chari, MD | EHA 2024
LINVOSELTAMAB in Patients with Relapsed/Refractory Myeloma | Suzanne Lentzsch MD, PhD | EHA 2024
Cevostamab in RRMM Patients: CAMMA 2 Study Results | Joshua Richter, MD | EHA 2024
ASCO/EHA 2024 Myeloma Highlights - IMROZ, DREAMM-7, DREAMM-8 | Joshua Richter, MD | EHA 2024


